Literature DB >> 28449737

Authors'reply: Concern regarding the alleged spread of hypervirulent lymphogranuloma venereum Chlamydia trachomatis strain in Europe.

Fruzsina Petrovay1, Eszter Balla1, Timea Erdősi2.   

Abstract

Entities:  

Keywords:  Chlamydia trachomatis; Hungary; bacterial infections; genovariant; lymphogranuloma venereum – LGV; men who have sex with men (MSM); sexually transmitted infections

Mesh:

Year:  2017        PMID: 28449737      PMCID: PMC5476978          DOI: 10.2807/1560-7917.ES.2017.22.15.30512

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


× No keyword cloud information.
To the editor: A recent letter by Chlamydia researchers [1] reflected on our article [2], raising a question about a potential misclassification of the published Hungarian LGV genotypes that we characterised as ‘L2c’. We agree with the authors of the letter that there is no established official nomenclature for lymphogranuloma venereum (LGV) genovariants. Moreover there are two so-called L2c variants reported in the literature, based on different typing methodologies [3,4]. The reference that we used to characterise the strains in our report was the L2c variant described by Somboonna et al. [4]. In particular, a partial sequence of the ompA gene of this variant was employed for typing, and, as stated in the letter, ‘It is important to recognise that the use of the term ‘L2c genotype’ in the case of the L2-D recombinant strain is a misnomer, as the ompA-genotype of this strain is an archetypal L2’, this sequence proved to be identical, at least at protein level, to the L2 sequence. This fact was clarified by the LGV Genotype Dynamics Study Group, University of Basel. Due to the confusing situation of the LGV nomenclature, we have contacted this LGV research laboratory aiming to further collaborate and subtype the DNA-samples of the reported Hungarian LGV strains. We would like to point out that the Hungarian genovariants differ from the L2b variant spreading in western European countries, as was confirmed by comparison to different reference sequences of L2b sent by the LGV Genotype Dynamics Study Group, who suggested to describe the Hungarian isolates as ‘L2‘ genovariants until further more detailed genomic analysis. As we do not know yet whether they prove to be a new L2 type or not, we recommend to wait with the classification of these strains until we have the final typing results. We agree that only further investigation, such as whole genomic sequencing and phylogenetic analysis can confirm the genomic background and these techniques may reveal some misnomers of LGV genotypes reported previously in other publications.
  4 in total

1.  New Chlamydia trachomatis L2 strains identified in a recent outbreak of lymphogranuloma venereum in Vienna, Austria.

Authors:  Georg Stary; Thomas Meyer; Christine Bangert; Norbert Kohrgruber; Bernd Gmeinhart; Reinhard Kirnbauer; Christian Jantschitsch; Armin Rieger; Angelika Stary; Alexandra Geusau
Journal:  Sex Transm Dis       Date:  2008-04       Impact factor: 2.830

2.  Hypervirulent Chlamydia trachomatis clinical strain is a recombinant between lymphogranuloma venereum (L(2)) and D lineages.

Authors:  Naraporn Somboonna; Raymond Wan; David M Ojcius; Matthew A Pettengill; Sandeep J Joseph; Alexander Chang; Ray Hsu; Timothy D Read; Deborah Dean
Journal:  MBio       Date:  2011-05-03       Impact factor: 7.867

3.  Concern regarding the alleged spread of hypervirulent lymphogranuloma venereum Chlamydia trachomatis strain in Europe.

Authors:  Helena Mb Seth-Smith; Juan C Galán; Daniel Goldenberger; David A Lewis; Olivia Peuchant; Cecile Bébéar; Bertille de Barbeyrac; Angele Bénard; Ian Carter; Jen Kok; Sylvia M Bruisten; Bart Versteeg; Servaas A Morré; Nicholas R Thomson; Adrian Egli; Henry Jc de Vries
Journal:  Euro Surveill       Date:  2017-04-13

4.  Emergence of the lymphogranuloma venereum L2c genovariant, Hungary, 2012 to 2016.

Authors:  Fruzsina Petrovay; Eszter Balla; Tímea Erdősi
Journal:  Euro Surveill       Date:  2017-02-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.